MedTrace Logo

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

NCT00779389 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2016-01-13

No results posted yet for this study

Summary

The central hypothesis to be tested in this study is that dual blockade of EGFR and Src pathways or proteins are distinct compared to inhibition of either kinase alone in head and neck and lung cancers.

Conditions

Interventions

DRUG

Erlotinib

Erlotinib 150mg will be taken once a day for 14-21days.

DRUG

Dasatinib + Placebo

Dasatinib (100 mg) once a day for 14-21 days.

DRUG

Erlotinib plus Dasatinib

Erlotinib (150 mg PO qD) plus Dasatinib (100 mg PO qD) 14-21 days

DRUG

Placebo

Placebo for 14-21 days.

DRUG

Erlotinib

Erlotinib 150 mg for 14-21 days.

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Jennifer R Grandis, MD · University of Pittsburgh Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00779389 on ClinicalTrials.gov